Editas Medicine Inc. (EDIT)
Editas Medicine Statistics
Share Statistics
Editas Medicine has 82.98M shares outstanding. The number of shares has increased by 0.9% in one year.
| Shares Outstanding | 82.98M |
| Shares Change (YoY) | 0.9% |
| Shares Change (QoQ) | 0.52% |
| Owned by Institutions (%) | 61.84% |
| Shares Floating | 82.23M |
| Failed to Deliver (FTD) Shares | 72 |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 19.15M, so 23.2% of the outstanding shares have been sold short.
| Short Interest | 19.15M |
| Short % of Shares Out | 23.2% |
| Short % of Float | 23.42% |
| Short Ratio (days to cover) | 6.43 |
Valuation Ratios
The PE ratio is -0.44 and the forward PE ratio is -0.98. Editas Medicine's PEG ratio is -0.01.
| PE Ratio | -0.44 |
| Forward PE | -0.98 |
| PS Ratio | 3.24 |
| Forward PS | 15.7 |
| PB Ratio | 0.78 |
| P/FCF Ratio | -0.48 |
| PEG Ratio | -0.01 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Editas Medicine.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.75, with a Debt / Equity ratio of 0.26.
| Current Ratio | 3.75 |
| Quick Ratio | 3.75 |
| Debt / Equity | 0.26 |
| Debt / EBITDA | -0.15 |
| Debt / FCF | -0.16 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $131.36K |
| Profits Per Employee | $-963.79K |
| Employee Count | 246 |
| Asset Turnover | 0.09 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -82.65% in the last 52 weeks. The beta is 1.87, so Editas Medicine's price volatility has been higher than the market average.
| Beta | 1.87 |
| 52-Week Price Change | -82.65% |
| 50-Day Moving Average | 1.5 |
| 200-Day Moving Average | 2.91 |
| Relative Strength Index (RSI) | 40.53 |
| Average Volume (20 Days) | 3.85M |
Income Statement
In the last 12 months, Editas Medicine had revenue of 32.31M and earned -237.09M in profits. Earnings per share was -2.88.
| Revenue | 32.31M |
| Gross Profit | 32.31M |
| Operating Income | -251.15M |
| Net Income | -237.09M |
| EBITDA | -233.11M |
| EBIT | -238.92M |
| Earnings Per Share (EPS) | -2.88 |
Balance Sheet
The company has 131.54M in cash and 35.03M in debt, giving a net cash position of 96.51M.
| Cash & Cash Equivalents | 131.54M |
| Total Debt | 35.03M |
| Net Cash | 96.51M |
| Retained Earnings | -1.47B |
| Total Assets | 341.59M |
| Working Capital | 212.09M |
Cash Flow
In the last 12 months, operating cash flow was -210.28M and capital expenditures -8.83M, giving a free cash flow of -219.11M.
| Operating Cash Flow | -210.28M |
| Capital Expenditures | -8.83M |
| Free Cash Flow | -219.11M |
| FCF Per Share | -2.66 |
Margins
Gross margin is 100%, with operating and profit margins of -777.22% and -733.72%.
| Gross Margin | 100% |
| Operating Margin | -777.22% |
| Pretax Margin | -733.72% |
| Profit Margin | -733.72% |
| EBITDA Margin | -721.39% |
| EBIT Margin | -777.22% |
| FCF Margin | -678.07% |
Dividends & Yields
EDIT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for EDIT is $7.5, which is 530.3% higher than the current price. The consensus rating is "Hold".
| Price Target | $7.5 |
| Price Target Difference | 530.3% |
| Analyst Consensus | Hold |
| Analyst Count | 14 |
Scores
| Altman Z-Score | -7.18 |
| Piotroski F-Score | 2 |